A child dying every 20 seconds is an unacceptable statistic – Stablepharma’s vision is for a world where lives are no longer destroyed by vaccine preventable diseases. Thanks to Dr Bruce Roser’s dedication and extensive research, Stablepharma is bringing to market a disruptive process to eradicate vaccine wastage, reduce costs and more importantly, stabilise lifesaving vaccines.
The huge benefit of StablevaX™ will be its unique ability to enable vaccines to be stored in even the most inhospitable parts of the world, negating the expensive and unreliable ‘Cold Chain’ and thereby allowing vaccines to reach everyone, everywhere.
What motivates us
Vaccines are thermally unstable products that lose their effectiveness if exposed to temperatures which are either too hot or too cold – and most require constant refrigeration between 2-8°C. The World Health Organisation (WHO) estimates that 50% of the world’s vaccines are rendered useless each year due to failings of the existing refrigeration processes (known as the ‘The Cold Chain’) used for delivery and storage.
The human cost
There are 3 million child deaths per annum that are currently prevented by vaccination – we want to help vastly improve this number. The “Cold Chain” failure reduces the effectiveness of vaccination programmes and this can lead to unnecessary deaths and the possible re-emergence of disease.
StablevaX™ will extend the shelf life of most vaccines at high temperatures, allowing for safe distribution and storage, for many years, without loss of potency.
The economic cost
The World Health Organization reports that over 50% of vaccines are wasted around the world each year.
The global cost of the ‘Cold Chain’ is estimated at $ 400 m per annum. It is unreliable, expensive and fails frequently. The global human vaccine market is estimated to be worth over $36 bn in 2018.
Product wastage of up to 50% is unacceptable.
Receive our investor information pack
Please enter your details below to receive our investor information pack